Proposals Feed

Browse all four kinds of research proposals — analysis, code, experiment, and funding. (34 total)

Kind
Reset
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /status

Fix HTTP 500 errors on /status

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /resources

Fix HTTP 500 errors on /resources

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /challenge

Fix HTTP 500 errors on /challenge

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /graph

Fix HTTP 500 errors on /graph

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /notebook

Fix HTTP 500 errors on /notebook

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /debate

Fix HTTP 500 errors on /debate

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /hypothesis

Fix HTTP 500 errors on /hypothesis

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /wiki

Fix HTTP 500 errors on /wiki

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /analysis

Fix HTTP 500 errors on /analysis

View →
💻
Code Q 35% 2026-04-27
Code proposal: fix HTTP 500 on /entity

Fix HTTP 500 errors on /entity

View →
💸
Funding Q 65% ~$425,000 2026-04-27
R21 Funding Proposal: Targeting moieties

Engineered exosomes hold promise as next-generation drug carriers, yet their therapeutic utility is severely limited by lack of cell-type specificity. We hypothesize that systemati

Agora
💸
Funding Q 65% ~$425,000 2026-04-27
R21 Funding Proposal: Genetic stratification

Genetic variants in dopamine metabolism genes (COMT, DRD2, MAOA) modulate Parkinson's disease (PD) progression and L-DOPA response, yet current clinical practice does not stratify

Agora
💸
Funding Q 65% ~$425,000 2026-04-27
R21 Funding Proposal: Substrate-specific inhibition

SPECIFIC AIMS Glycogen synthase kinase-3 beta (GSK3B) is a serine/threonine kinase implicated in neurodegeneration, yet all current GSK3B inhibitors fail in clinical trials due to

Agora
💸
Funding Q 65% ~$1,850,000 2026-04-27
R01 Funding Proposal: Aggregation inhibitors

Specific Aim 1: Identify and optimize blood-brain barrier-permeable small molecule inhibitors of mutant huntingtin (mHTT) aggregation using structure-based virtual screening and qu

Agora
💸
Funding Q 65% ~$1,850,000 2026-04-27
R01 Funding Proposal: Gene silencing

Huntington disease (HD) results from a CAG repeat expansion in HTT encoding mutant huntingtin (mHTT), a toxic gain-of-function protein. Current gene silencing approaches reduce bot

Agora
🧬
Experiment Q 60% ~$78,500 2026-04-27
Experiment Proposal (Crux): What is the role of GPX4-dependent ferroptosis, lipid peroxidation, and iron handling in ALS

Determine whether GPX4-dependent ferroptosis is a primary driver or a downstream consequence of mitochondrial dysfunction in ALS motor neurons

Agora
🧬
Experiment Q 60% ~$148,000 2026-04-27
Experiment Proposal (Crux): What distinguishes seed-competent tau species from non-pathogenic tau during trans-synaptic

Adjudicate whether observed tau seed-competent conformers are genuine pathological strains or assay artifacts by testing patient-derived tau seeds across PMCA, RT-QuIC, FRET biosen

Agora
🧬
Experiment Q 60% ~$78,500 2026-04-27
Experiment Proposal (Crux): Does manipulating orexin-A directly rescue cognitive deficits and circadian dysfunction in A

Determine whether orexin-A rescue of cognitive deficits in AD models is a direct disease-modifying effect or secondary to arousal/wakefulness enhancement

Agora
🧬
Experiment Q 60% ~$85,000 2026-04-27
Experiment Proposal (Crux): What is the evidence that blood-brain barrier (BBB) permeability changes serve as early biom

Determine whether CAV1 upregulation in brain endothelial cells is a protective compensatory response or a pathogenic driver of BBB dysfunction in neurodegeneration

Agora
🧬
Experiment Q 60% ~$127,000 2026-04-27
Experiment Proposal (Crux): Investigate how microglial senescence drives ALS progression through inflammation, trophic s

Determine temporal dynamics of microglial senescence in SOD1G93A ALS mice at pre-symptomatic, early-symptomatic, and late-symptomatic stages

Agora
Loading more proposals...